業績

業績

2016年度/2017年度/2018年度/2019年度/2020年度

2020年度

  1. Tahara N, Dobashi H, Fukuda K, Funauchi M, Hatano M, Ikeda S, Joho S, Kihara Y, Kondo T, Matsushita M, Minamino T, Nakanishi N, Okano Y, Ozaki Y, Saji T, Sakai S, Tanabe N, Watanabe H, Yamada H, Yoshioka K, Hatta M, Sasayama S: Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients. Curr Med Res Opin, 12:1-8.doi:10.1080/ 03007995.2020. 1756234, 2020.
  2. Aono Y, Nakamura Y, Kono M, Nakamura H, Yokomura K, Imokawa S, Toyoshima M, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Inui N, Suda T: Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Ther Adv Respir Dis, 14,1753466620953783, 2020.
  3. Aoshima Y, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Mikamo M, Matsuura S, Kusagaya H, Kaida Y, Uto T, Hashimoto D, Matsui T, Asada K, Suda T: Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Invest New Drugs,39/1,210-216,2020.
  4. Koyauchi T, Yasui H, Enomoto N, Hasegawa H, Hozumi H, Suzuki Y, Karayama M, Furuhashi K, Fujisawa T, Nakamura Y, Inui N, Yokomura K, Suda T:Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease. Ther Adv Respir Dis, 14,1753466620906327, 2020.
  5. Koyauchi T, Inui N, Karayama M, Kitahara Y, Takuma S, Amano Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Niwa M, Inami N, Ito Y, Kusagaya H, Matsuura S, Kaida Y, Uto T, Hashimoto D, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Suda T: Clinical Outcomes of Anti-programmed Death-1 Antibody–Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. SN Compr. Clin. Med 2: 570–578, 2020.
  6. Akiyama N, Hozumi H, Isayama T, Okada J, Sugiura K, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Inui N, Nakamura Y, Suda T: Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis. Respirology (Carlton, Vic.)25/7,743-749, 2020.
  7. Kamiya Y, Fujisawa T, Katsumata M, Yasui H, Suzuki Y, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Setou M, Ito M, Suzuki T, Ikegami K, Suda T: Influenza A virus enhances ciliary activity and mucociliary clearance via TLR3 in airway epithelium. Respiratory research, 21/1,282,2020.
  8. Inoue Y, Yoshimura K, Nishimoto K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Kusagaya H, Matsuda H, Inami N, Kaida Y, Niwa M, Ito Y, Sugimura H, Suda T: Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer. JAMA network open, 3/9,e2011818, 2020.
  9. Suzuki Y, Fujisawa T, Sumikawa H, Tanaka T, Sugimoto C, Kono M, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T: Disease course and prognosis of pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis. Respiratory medicine.171,106078, 2020.
  10. Tanaka K, Enomoto N, Uehara M, Furuhashi K, Sakurai S, Yasui H, Karayama M, Hozumi H, Suzuki Y, Fujisawa T, Inui N, Nakamura Y, Nagata T, Suda T: Development of a novel T cell-oriented vaccine using CTL/Th-hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium.Microbiology and immunology,64/10,666-678,2020.
  11. Ito K, Murotani K, Kubo A, Kunii E, Taniguchi H, Shindoh J, Asada K, Imaizumi K, Takahashi K, Karayama M, Okuno M, Inui N, Hataji O, Morikawa S, Hayai S, Suda T, Abe T, Tsuda T, Yamagichi T, Kimura T, Oya Y, Yoshida T, Hida T: Cancer science Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.111/10,3705-3713,2020.
  12. Nishimoto K, Fujisawa T, Yoshimura K, Enomoto Y, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Sumikawa H, Johkoh T, Suda T: Pneumothorax in connective tissue disease-associated interstitial lung disease. PloS one,15/7,e0235624.2020.
  13. Akiyama N, Fujisawa T, Morita T, Mori K, Yasui H, Hozumi H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T: Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View. Journal of pain and symptom management,60/5,933-940,2020.
  14. Yoshimura K, Suzuki Y, Inoue Y, Tsuchiya K, Karayama M, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K, Shinmura K, Niwa H, Sugimura H, Suda T: CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer. Oncoimmunology,9/1,1746554,2020.
  15. Yoshimura K, Saku A, Karayama M, Inui N, Sugimura H, Suda T: Leucine-Rich α-Glycoprotein as a Potential Biomarker for Immune-related Colitis After Anti-PD-L1 Therapy: A Report of a Case Series. Clinical lung cancer, 21/6,e516-e522,2020.
  16. Suzuki Y, Karayama M, Uto T, Fujii M, Matsui T, Asada K, Kusagaya H, Kato M, Matsuda H, Matsuura S, Toyoshima M, Mori K, Ito Y, Koyauchi T, Yasui H, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T: Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,15/8,1317-1327,2020.
  17. Karayama M, Yoshizawa N, Sugiyama M, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Goshima S, Suda T, Takehara Y: Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 143,47-54,2020.
  18. Tsuchiya K, Suzuki Y, Yoshimura K, Yasui H, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Yokomura K, Suda T: Author Correction: Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia.Scientific reports,10/1,3324, 2020.
  19. Matsushima S, Aoshima Y, Akamatsu T, Enomoto Y, Meguro S, Kosugi I, Kawasaki H, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Funai K, Suda T: Iwashita T. CD248 and integrin alpha-8 are candidate markers for differentiating lung fibroblast subtypes.BMC pulmonary medicine 20/1,21,2020.
  20. Yoshimura K, Inoue Y, Tsuchiya K, Karayama M, Yamada H, Iwashita Y, Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K, Shinmura K, Niwa H, Suda T:Sugimura H: Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 141,21-31,2020.
  21. Ito T, Sato T, Hakamata A, Onoda Y, Sato S, Yamazaki F, Horikawa M, Takahashi Y, Kitamoto T, Suzuki M, Uchida S, Odagiri K, Setou M. A nonrandomized study of single oral supplementation within the daily tolerable upper level of nicotinamide affects blood nicotinamide and NAD+ levels in healthy subjects. Translational Medicine of Aging 2020, 4, 45-54
  22. Tanaka S, Uchida S, Hakamata A, Miyakawa S, Odagiri K, Inui N, Watanabe H, Namiki N. Simultaneous LC-MS Analysis of Plasma Concentrations of Sildenafil, Tadalafil, Bosentan, Ambrisentan, and Macitentan in Patients With Pulmonary Arterial Hypertension. Pharmazie . 2020 Jun 1;75(6):236-239. doi: 10.1691/ph.2020.0021.
戻る

2019年度

  1. Kamiya C, Inui N, Hakamata A, Miyakawa S, Tanaka S, Uchida S, Namiki N, Odagiri K, Watanabe H:Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci, S1347-8613(19) : 30032-30035 doi: 10.1016/j.jphs.2019.03.001, 2019.
  2. Kamiya C, Odagiri K , Hakamata A, Inui N, Watanabe H: Clinical Outcomes and Treatment Options in Patients With Pulmonary Hypertension Who Received Pulmonary Hypertension-Specific Drugs-Single-Center Case Series-. Circulation Reports, 1: 389-395doi:10.1253/circrep.CR-19-0059, 2019.
  3. Katayama N, Odagiri K, Hakamata A, Inui N, Yamauchi K, Watanabe H: Transient Laterality of Cerebral Oxygenation Changes in Response to Head-of-Bed Mainpulation in Acute Ischemic Stroke. J.Clin.Med, 8,1739: doi:10.3390/jcm8101739, 2019.
  4. Sai K, Yoshida A, Hanatani T, Imatoh T, Takeuchi M, Narukawa M, Watanabe H, Uyama Y, Saito Y: Population/regional differences in efficacy of 3 drug categories (antidiabetic, respiratory and psychotropic agents) among East Asians: A retrospective study based on multiregional clinical trials. Br J Clin Pharmacol,doi: 10.1111/bcp. 13893, 2019.
  5. Takano H, Uchida S, Kashiwagura Y, Tanaka S, Hakamata A, Odagiri K , Inui N, Watanabe H, Namiki N: Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability. Chem Pharm Bull (Tokyo), 67(2): 112-119 doi: 10.1248/cpb.c18-00629,2019.
  6. Yasui H, Inui N, Karayama M, Mori K, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T: Correlation of the modified Medical Research Council dyspnea scale with airway structure assessed by three-dimensional CT in patients with chronic obstructive pulmonary disease. Respir Med, 146: 76-80 doi: 10.1016/j.rmed.2018.11.020, 2019.
  7. Sakurada R,Odagiri K, Hakamata A, Kamiya K,Wei Jiazhng, Watanabe H: Calcium Release from Endoplasmic Reiculum Involves Calmodulin-Mediated NADPH Oxidase-Endothelial Cells. Int.J. Mol.Sci, 20: 1644doi: 10.3390/ijms20071644, 2019.
  8. Satoyama M, Uchida S, Kamiya C, Tanaka S, Kashiwagura Y, Hakamata A, Odagiri K, Inui N, Watanabe H, Namiki N: Ease of Talking Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.Chem Pharm Bull (Tokyo),67(6): 540-545, 2019.
  9. Akiyama N, Inui N, Mori K, Nakamura Y, Hayakawa H, Tanaka S, Uchida S, Namiki N, Watanabe H, Suda T:Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex. J Thorac Dis, 11(9): 3814-3821,2019.
  10. Miura M, Uchida S, Tanaka S, Inui N, Kawakami J, Watanabe H, Namiki N: The Prediction of the Area under the Curve and Clearance of Midazolam from Single-Point Plasma Concentration and Urinary Excretion in Healthy Volunteers. Biol Pharm Bul,42(9):1590-1595,2019.
  11. Kozu K, Sugimura K, Ito M, Hirata KI, Node K, Miyamoto T, Ueno S, Watanabe H, Shimokawa H: Japanese Pulmonary Circulation Study Group.:Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan.Int J Cardiol, 300:228-235 doi:10.1016/j.ijcard.2019. 11.139, 2019.
  12. Takenouchi K, Yuasa K, Shioya M, Kimura M, Watanabe H, Oki Y, Hakamata A, Watanabe H, Fukushima M:Development of a new seamless data stream from EMR to EDC system using SS-MIX2 standards applied for observational research in diabetes mellitus.Learn Health Syst, 15;3(1): e10072. doi: 10.1002/lrh2.10072, 2019.
  13. Karayama M, Inui N, Yasui H, Kono M, Hozumi H, Suzuki Y, Furuhashi K, Hashimoto D, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T:Clinical features of three-dimensional computed tomography-based radiologic phenotypes of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 14:1333-1342, 2019.
  14. Karayama M, Inui N, Yasui H, Kono M, Hozumi H, Suzuki Y, Furuhashi K, Hashimoto D, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T: Physiological and morphological differences of airways between COPD and asthma-COPD overlap. Sci Rep, 9(1): 7818, 2019.
  15. Akiyama N, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Uto T, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Suda T: Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. Invest New Drugs, 37/3,531-537, 2019 .
  16. Hozumi H, Hasegawa H, Miyashita K, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Hashimoto D, Enomoto N, Fujisawa T, Inui N, Nakamura Y, Yokomura K, Nakamura H, Suda T: Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis. Respirology, 24/8,792-798,2019.
  17. Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Enomoto N, Inui N, Nakamura Y, Mimori T, Suda T: Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis. J Rheumatol. 46/5,509-517, 2019.
  18. Enomoto N, Oyama Y, Enomoto Y, Yasui H, Karayama M, Kono M, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Inui N, Nakamura Y, Suda T: Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. Chron Respir Dis, 16: 14799723188094 76, 2019.
  19. Tsuchiya K, Suzuki Y, Yoshimura K, Yasui H, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Yokomura K, Suda T: Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia. Scientific reports, 9/1,18750, 2019.
  20. Kamiya Y, Fujisawa T, Kono M, Nakamura H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Sumikawa H, Johkoh T, Yasui H, Hozumi H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T:Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases. Respiratory medicine,159,105811,2019.
  21. Suzuki Y, Inui N, Karayama M, Imokawa S, Yamada T, Yokomura K, Asada K, Kusagaya H, Kaida Y, Matsuda H, Koshimizu N, Toyoshima M, Masuda M, Hayakawa H, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Suda T: Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD. International journal of chronic obstructive pulmonary disease, 14,1867-1877, 2019.
  22. Furuhashi K, Fujisawa T, Hashimoto D, Kamiya Y, Yasui H, Karayama M, Suzuki Y, Hozumi H, Enomoto N, Nakamura Y, Inui N, Suda T: Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial. Journal of asthma and allergy, 12,253-261,2019.
  23. Kono M, Nakamura Y, Enomoto N, Saito G, Koyanagi Y, Miyashita K, Tsutsumi A, Kobayashi T, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Miki Y, Hashimoto D, Fujisawa T, Inui N, Suda T, Nakamura H: Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. Respiratory investigation, 57/6,552-560, 2019.
  24. Sugawara S, Inui N, Kanehara M, Morise M, Yoshimori K, Kumagai T, Fukui T, Minato K, Iwashima A,Takeda Y, Kubota K, Saeki T, Tamura T: Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Cancer,125/22,4076-4083, 2019.
  25. Akahori D, Suzuki Y, Yokomura K, Shirai M, Yasui H, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Hayakawa H, Suda T: Body composition changes successfully classify prognosis in patients with mycobacterium avium complex lung disease. The Journal of infection,79/4,341-348, 2019.
  26. Tsuchiya K, Karayama M, Sato T, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T,Nakamura Y, Inui N, Sugimura H, Yasuda H, Suda T: Simultaneous Occurrence of Sarcoidosis and Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis in a Patient with Lung Cancer. Internal medicine (Tokyo, Japan),58/22,3299-3304, 2019.
  27. Enomoto N, Oyama Y, Yasui H, Karayama M, Hozumi H, Suzuki Y, Kono M, Furuhashi K, Fujisawa T, Inui N, Nakamura Y, Suda T: Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis. Scientific reports. 9/1,10484, 2019.
  28. Aoshima Y, Karayama M, Sagisaka S, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T: Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer. Internal medicine (Tokyo, Japan),58/22,3267-3271,2019.
  29. Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T: Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease. The Journal of rheumatology, 46/8,935-942,2019.
  30. Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kusagaya H, Matsuura S, Uto T, Hashimoto D, Matsui T, Asada K, Suda T: Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer chemotherapy and pharmacology, 84/1,147-153, 2019.
  31. Tsuchiya K, Suzuki Y, Yasui H, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Fujisawa T,Nakamura Y, Inui N, Baba S, Suda T: Methotrexate-associated Lymphoproliferative Disorder with Diffuse Ground-Glass Opacities. American journal of respiratory and critical care medicine, 199/8,1031-1033. 2019.
  32. 栗原千絵子,鈴木千恵子,小池竜司,佐藤弥生,渡邉裕司:臨床研究法の現状における課題と運用改善に向けた提言:GCP・医学系指針及び海外制度との比較から-第1報 医薬品等の品質・安全性の確保-.臨床評価, 47(1): 127-152,2019.
  33. 小早川雅男,寺田麻里,大津洋,泉和生,齋藤翔,北條奏輔,渡邉裕司: NIH and FDA Release Protocol Template for Phase2 and 3 IND/IDE Clinical Trialsの取り組み. 臨床薬理,49(1):35-38,2019.
  34. 小池竜司,栗原千絵子,鈴木千恵子,佐藤弥生,星順子,渡邉裕司:医師主導治験・医学研究における健康被害補償に関する調査.臨床薬理, 50(4): 157-166,2019 .
  35. 田中紫茉子,内田信也,渡邉裕司,並木徳之:薬物相互作用の迅速・網羅的検出を目的とした低侵襲カクテル試験の確立.臨床薬理の進歩,40: 17-26, 2019.
  36. 寺田麻里,小早川雅男,大津洋,齋藤翔,北川明,泉和生,渡邉裕司:臨床研究の推進及び円滑化を目的としたひな形作成に関する取り組み-NIH-FDA Clinical Trial Protocol Templateと日本の規制に合わせた検討-.臨床薬理, 50(4): 183-196, 2019.
戻る

2018年度

  1. Watanabe H: Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator. Eur Cardiol, 13(1):35-37doi: 10.15420/ecr. 2017:22:2. Review, 2018.
  2. Katayama T, Uchida S, Kamiya C, Tanaka S, Kashiwagura Y, Hakamata A, Odagiri K, Inui N, Watanabe H, Namiki N: In vivo drug dissolution in human oral cavity from orally disintegrating tablet and comparability with in vitro testing. Chemical and Pharmaceutical Bulletin, 66(10):999-1005doi: 10.1248/cpb.c18-00492, 2018.
  3. Nishimoto K, Karayama M, Inui N, Mori K, Kono M, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T:Relationship between fraction of exhaled nitric oxide and airway morphology assessed by three-dimensional CT analysis in asthma.Sci Rep,7(1):10187doi: 10.1038/s41598-017-10504-w, 2018.
  4. Nishimoto K, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Imokawa S, Suda T:Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study. Med Oncol,35(7): 108, 2018.
  5. Kato S, Inui N, Hozumi H, Inoue Y, Yasui H, Karayama M, Kono M, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T:Neutrophil gelatinase-associated lipocalin in patients with sarcoidosis. Respir Med, 138S:S20-S23 doi: 10.1016/j.rmed.2018.01.004, 2018.
  6. Karayama M, Inui N, Mori K, Kono M, Hozumi H, Suzuki Y, Furuhashi K, Hashimoto D, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T: Respiratory impedance is correlated with airway narrowing in asthma using three-dimensional computed tomography. Clin Exp Allergy, 48(3):278-287doi: 10.1111/cea.13083, 2018.
  7. Karayama M, Inui N, Tanaka K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Suda T: Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis. Med Oncol, 35(11):139, 2018.
  8. Kato S, Inui N, Hakamata A, Suzuki Y, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T:Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis. Respir Res,19(1):127doi: 10.1186/s12931-018-0831-y, 2018.
  9. Enomoto Y, Matsushima S, Meguro S, Kawasaki H, Kosugi I, Fujisawa T, Enomoto N, Inui N, Nakamura Y, Suda T, Iwashita T. Podoplanin-positive myofibroblasts: a pathological hallmark of pleuroparenchymal fibroelastosis. Histopathology, 72/7,1209-1215, 2018.
  10. Mikamo M, Kitagawa K, Sakai S, Uchida C, Ohhata T, Nishimoto K, Niida H, Suzuki S, Nakayama KI, Inui N, Suda T: Kitagawa M. Inhibiting Skp2 E3 Ligase Suppresses bleomycin-induced pulmonary fibrosis. Int J Mol Sci, 19(2), 2018.
  11. Uehara M, Enomoto N, Oyama Y, Suzuki Y, Kono M, Furuhashi K, Fujisawa T, Inui N, Nakamura Y, Suda T:Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Respirology, 23(3):318-324, 2018.
  12. Yasui H, Inui N, Fujisawa T, Karayama M, Enomoto N, Nakamura Y, Kuroishi S, Ohba H, Yokomura K, Sato J, Sato M, Koshimizu N, Toyoshima M, Yamada T, Masuda M, Shirai T, Suda T: Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease. Clin Med Insights Circ Respir Pulm Med, 12:1179548418771702, 2018.
  13. Suzuki Y, Yoshimura K, Enomoto Y, Yasui H, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T: Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis. Sci Rep, 8(1): 14074, 2018.
  14. Niwa M, Fujisawa T, Mori K, Yamanaka K, Yasui H, Suzuki Y, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suzuki T: Maekawa M, Suda T. IL-17A Attenuates IFN-λ Expression by Inducing Suppressor of Cytokine Signaling Expression in Airway Epithelium. J Immunol, 201(8): 2392-2402, 2018.
  15. Suzuki Y, Shirai M, Asada K, Yasui H, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Shirai T, Hayakawa H, Suda T: Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis. Sci Rep, 8(1):13129, 2018.
  16. Niwa M, Fujisawa T, Karayama M, Furuhashi K, Mori K, Hashimoto D, Yasui H, Suzuki Y, Hozumi H, Enomoto N, Nakamura Y, Inui N, Suda T: Differences in airway structural changes assessed by 3-dimensional computed tomography in asthma and asthma-chronic obstructive pulmonary disease overlap. Ann Allergy Asthma Immunol,21(6):704-710, 2018.
  17. Enomoto Y, Matsushima S, Shibata K, Aoshima Y, Yagi H, Meguro S, Kawasaki H, Kosugi I, Fujisawa T, Enomoto N, Inui N, Nakamura Y, Suda T: Iwashita T. LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis. Clin Sci (Lond), 132(14):1565-1580, 2018.
  18. Hozumi H, Oyama Y, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Inui N, Nakamura Y, Suda T: Clinical significance of myeloperoxidase- anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. PLoS One, 13(6): e0199659, 2018.
  19. Enomoto N, Oyama Y, Enomoto Y, Mikamo M, Karayama M, Hozumi H, Suzuki Y, Kono M, Furuhashi K, Fujisawa T, Inui N, Nakamura Y, Suda T: Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis. Clin Respir J, 12(8): 2378-2389, 2018.
  20. Yoshimura K, Suzuki Y, Inoue Y, Nishimoto K, Mori K, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Yokomura K, Imokawa S, Suda T: Utility of serum Aspergillus-galactomannan antigen to evaluate the risk of severe acute exacerbation in chronic obstructive pulmonary disease. PLoS One, 13(6): e0198479, 2018.
  21. Yoshimura K, Kono M, Enomoto Y, Nishimoto K, Oyama Y, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N: Sumikawa H, Johkoh T, Colby TV, Sugimura H, Suda T. Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia. Respir Med, 137:167-175, 2018.
  22. 鍋岡勇造,栗原千絵子,三村まり子,小池竜司,渡邉裕司:治験/臨床研究に起因する健康被害の治療に対する公的医療保険制度の運用について.臨床評価,45(4)701-709,2018.
  23. 栗原千絵子,小池竜司,岡田潔,鈴木千恵子,星順子,佐藤弥生,村山敏典,山本学,渡邉裕司:医薬品・医療機器・再生医療等製品の企業主導・医師主導治験のおける被験者健康被害補償:共通点・相違点と医法研ガイドライン適用性.臨床評価,46(2):335-383,2018.
戻る

2017年度

  1. Obata Y, Takeuchi K, Wei J, Hakamata A, Odagiri K, Nakajima Y, Watanabe H: Interactions between bradykinin and plasmin in the endothelial Ca2+ response. Mol Cell Biochem, doi: 10.1007/s11010-017-3263-y, 2017 .
  2. Tanabe N, Ikeda S, Tahara N, Fukuda K, Hatano M, Ito H, Nakayama T, Anzai T, Hashimoto A, Inoue T,Kajinami K, Kihara Y, Kinoshita H, Kuwahara K, Murohara T, Okazaki O, Sakai S,Satoh T, Takeda Y, Takeishi Y, Taniguchi M, Watanabe H, Yamamoto T, Yamauchi-Takihara K, Yoshioka K, Sasayama S:Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.Circulation Journal, Article ID:CJ-16-1348,2017.
  3. Yasumuro O, Uchida S, Kashiwagura Y, Suzuki A,Tanaka S, Inui N, Watanabe H, Namiki N:Changes in gefitinib, erlotinib, and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. Xenobiotica, Oct 21:1-24doi: 10.1080/ 00498254.2017.1396379,2017.
  4. Sotoyama M, Uchida S, Tanaka S, Hakamata A, Odagiri K, Inui N, Watanabe H, Namiki N: Citric Acid Suppresses the Bitter Taste of Olopatadine Hydrochloride Orally Disintegrating Tablets. Biol Pharm Bull, 40(4):451-457, 2017.
  5. Nishimoto K, Fujisawa T, Yoshimura K, Enomoto Y, Enomoto N, Nakamura Y, Inui N, Sumikawa H, Johkoh T, Colby TV, Suda T: The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis. Respirology, 2017.
  6. Suzuki Y, Oyama Y, Hozumi H, Imokawa S, Toyoshima M, Yokomura K, Nakamura H, Kuroishi S, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Koshimizu N, Yamada T, Mori K, Masuda M, Shirai T, Hayakawa H, Sumikawa H, Johkoh T, Suda T: Persistent impairment on spirometry in chronic eosinophilic pneumonia: A longitudinal observation study (Shizuoka-CEP study). Ann Allergy Asthma Immunol,119(5):422-428.e2, 2017.
  7. Hozumi H, Fujisawa T, Enomoto N, Nakashima R, Enomoto Y, Suzuki Y, Kono M, Karayama M, Furuhashi K, Murakami A, Inui N, Nakamura Y, Mimori T, Suda T: Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease. J Rheumatol,44(9):1394-1401, 2017.
  8. Yoshimura K, Inoue Y, Mori K, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K, Shinmura K, Niwa H, Suda T: Sugimura H. Distinct prognostic roles and heterogeneity of TTF1 copy number and TTF1 protein expression in non-small cell lung cancer. Genes Chromosomes Cancer,6(7):570-581, 2017.
  9. Suzuki Y, Shirai M, Asada K, Miwa S, Karayama M, Nakamura Y, Inui N, Shirai T, Hayakawa H, Baba S, Suda T: Utility of Macrophage-activated Marker CD163 for Diagnosis and Prognosis in Pulmonary Tuberculosis. Ann Am Thorac Soc,14(1): 57-64, 2017.
  10. Satake Y, Nakamura Y, Kono M, Hozumi H, Nagata T, Tsujimura K, Enomoto N, Fujisawa T, Inui N, Fujiyama T, Tokura Y, Matsui T, Yokomura K, Shirai M, Hayakawa H, Suda T: Type-1 polarised dendritic cells are a potent immunogen against Mycobacterium tuberculosis. Int J Tuberc Lung Dis, 21:523-530,2017.
  11. Inoue Y, Matsuura S, Yoshimura K, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, Maeda M, Ogawa H, Inui N, Funai K, Shinmura K, Niwa H, Suda T, Sugimura H: Characterization of V-set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells. Cancer Sci, 108(8):1701-1714, 2017.
  12. Enomoto Y, Nakamura Y, Colby TV, Johkoh T, Sumikawa H, Nishimoto K, Yoshimura K, Matsushima S, Oyama Y, Hozumi H, Kono M, Fujisawa T, Enomoto N, Inui N, Iwashita T, Suda T: Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. PLoS One, 12(6):e0180283, 2017.
  13. Enomoto Y, Nakamura Y, Satake Y, Sumikawa H, Johkoh T, Colby TV, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Inui N, Iwashita T, Kuroishi S, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Yamada T, Shirai T, Hayakawa H, Suda T: Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study. Respir Med, 133:1-5, 2017
戻る

2016年度

  1. Hakamata A, Odagiri K, Miyakawa S, Irisawa H, Takeuchi K, Inui N, Tanaka S, Uchida S, Watanabe H:Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. Clin Transl Sci, 9(1):29-35, 2016.
  2. Wei J, Watanabe Y, Takeuchi K, Yamashita K, Tashiro M, Kita S, Iwamoto T, Watanabe H, Kimura J: Nicorandil stimulates a Na⁺/Ca⁺ exchanger by activating guanylate cyclase in guinea pig cardiac myocytes. Pflugers Arch, 468 doi: 10.1007/s00424-015-1763-8:693-703, 2016.
  3. Odagiri K, Inui N, Hakamata A, Inoue Y, Suda T, Takehara Y, Sakahara H, Sugiyama M, Alley M, Wakayama T, Watanabe H:Non-invasive evaluation of pulmonary arterial blood flow and wall shear stress in pulmonary arterial hypertension with 3D phase contrast magnetic resonance imaging. SpringerPlus, DOI.10.1186/s40064-016-2755-7,2016.
  4. Sato R, Tsuchiya KJ, Matsuzaki H, Takei N, Itoh H, Kanayama N, Suda T, Watanabe H, Ohashi T, Tanaka M, Nishimura S, Maekawa M, HBC study group:Fetal Environment and Glycosylation Status in Neonatal Cord Blood: A Comprehensive Mass Spectrometry-based Glycosylation Analysis. Medicine (Baltimore),95(14):e3219,2016.
  5. Sato R, Shirai K, Maekawa M, Genma R, Ohki S, Morita H, Suda T, Watanabe H: Glycaemia and autistic traits in very low birth weight infants in adulthood. Diabetes Metab,Sep;42(4):285-286,2016.
  6. Hasunuma T, Tohkin M, Kaniwa N, Jang l J, Yimin C, Kaneko M, Saito Y, Takeuchi M, Watanabe H, Yamazoe Y, Uyama Y, Kawai S:Absence of ethnic difference in the phamacokinetics of moxifloxacin, simvastatin and meloxicam among three East Asian population and Caucasians.Br. J. Clin Pharmacol, doi: 10.1111/cts.12384,2016.
  7. Tahara N, Dobashi H, Fukuda K, Funauchi M, Hatano M, Ikeda S, Joho S, Kihara Y, Kimura T, Kondo T, Matsushita M, Minamino T, Nakanishi N, Ozaki Y, Saji T, Sakai S, Tanabe N, Watanabe H, Yamada H, Yoshioka K, Sasayama S:Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.Circulation Journal, 80(6):1478-1483,2016.
  8. Kurihara C, Hoshi J, Suzuki C, Suzuki K, Kasai H, Morishita N,Sato Y, Suhara T and Watanabe H:Compensation,Insurance,and Management of Injuries in Investigator-Initiated Clinical Trials in Japan. Jpn J Clin Pharmacol Ther,47(6):219-228,2016.
  9. Suzuki S, Karayama M, Inui N, Fujisawa T, Enomoto N, Nakamura Y, Kuroishi S, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Asada K, Masuda M, Yamada T, Watanabe H, Suda T:Continuation maintenance therapy with S-1 in chemotherapy-naive patients with advanced squamous cell lung cancer.Invest New Drugs,34(4):490-496,2016.
  10. Suzuki S, Karayama M, Inui N, Kuroishi S, Fujisawa T, Enomoto N, Nakamura Y, Yokomura K, Toyoshima M, Imokawa S, Asada K, Masuda M, Yamada T, Watanabe H, Hayakawa H, Suda T:Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy. Med Oncol,33(7):65,2016.
  11. Igarashi A, Inoue S, Ishii T, Tsutani K, Watanabe H :Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension.Int Heart J,57(4):466-472,2016.
  12. Karayama M, Inui N, Fujisawa T, Enomoto N, Nakamura Y, Kuroishi S, Yokomura K, Koshimizu N, Sato M, Toyoshima M, Shirai T, Masuda M, Yamada T, Imokawa S, Suda T: Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer. Eur J Cancer, 58:30-37, 2016.
  13. 笠井宏委,栗原千絵子,鈴木千恵子,森下典子,星順子,佐藤弥生,渡邉裕司:医療機関における被験者健康被害補償のあり方に関する研究-実施医療機関における補償体制の整備に関する検討-.臨床評価,44(2): 329-368, 2016.
  14. 小田切圭一,袴田 晃央,乾 直輝,田中 紫茉子,内田 信也,渡邉 裕司:チトクロームP450フェノタイプが薬物による酵素誘導/阻害の程度に及ぼす影響の検討.臨床薬理の進歩,37: 120-127, 2016.
戻る